Gram-negative bacillary infections continue to be a major cause of morbidity and mortality among hospitalized patients. The introduction of newer antibiotics, such as gentamicin and carbenicillin, has altered the spectrum of these infections (H. Y. Chang, G. Narboni, V. Rodriguez, G. P. Bodey, and E. J. Freireich, Medicine, in press ). An increasing number of infections is caused by Klebsiella pneumoniae and Serratia marcescens (3) . A substantial number of these organisms is resistant to most of the currently available antibiotics. Hence, the search for new antibiotics and new congeners of existing antibiotics continues to be important.
Cefamandole is one of the new cephalosporin derivatives that is highly active against many gram-positive cocci and gram-negative bacilli. The sodium salt of the formyl ester of this antibiotic (cefamandole nafate) has been formulated for clinical use. This ester rapidly hydrolyzes in vivo to the parent compound. Since cefamandole has been reported to be more active than other cephalosporins in vitro, we have evaluated its activity against clinical isolates at this institution where a substantial proportion of isolates of Escherichia coli and K. pneumoniae is resistant to other cephalosporins.
MATERIALS AND METHODS
Susceptibility tests were conducted on 408 clinical isolates of gram-negative bacilli and 132 clinical isolates of gram-positive cocci, using the serial dilution technique with an automatic microtiter system (Canalco; Autotiter IV instruction manual). The organisms were inoculated into Mueller-Hinton broth (Difco) and incubated at 37 C for 18 h. A 0.05-ml sample of 10-i dilution of the broth cultures of gramnegative bacilli (approximately 105 colony-forming units/ml) was used as the inoculum for the susceptibility tests. A 0.05-ml sample of a 10-2 dilution ofthe broth cultures of gram-positive cocci (approximately 100 colony-forming units/ml) was used as the inoculum.
All gram-negative bacilli used in this study were cultured from blood specimens collected from cancer patients at this institution between 1970 and 1975. A total of 100 isolates each of E. coli, K. pneumoniae, and Proteus mirabilis, 50 isolates of S. marcescens, and 29 isolates each of indole-positive Proteus spp. and Enterobacter spp. were tested. All gram-positive cocci were cultured from specimens collected from hospitalized patients, most of whom did not have cancer. A total of 100 isolates of Staphylococcus aureus, 25 isolates of Streptococcus pyogenes, and 7 isolates of S. pneumoniae were tested. The susceptibility of isolates of S. aureus to penicillin G was determined by the broth dilution method. Isolates inhibited by less than 0.10 ,ug/ml were selected as penicillin G susceptible, and isolates resistant to more than 25 ug/ml were selected as penicillin G resistant.
Cefamandole, cephalothin, and cephalexin used in this study were supplied by Eli Lilly & Co., Indianapolis, Ind. Cefoxitin was supplied by Merck, Sharp and Dohme Research Laboratories, Rahway, N.J. Twofold serial dilutions of the antibiotics were prepared with Mueller-Hinton broth, and the minimum inhibitory concentration (MIC) was determined after incubation at 37 C for 18 h. All wells containing trace growth or no discernible growth were subcultured on sheep blood agar. A calibrated pipette was used to transfer 0.01 ml of the inoculum. The minimum bactericidal concentration (MBC) was determined after incubation at 37 C for 18 h. The MBC was defined as the lowest concentration of drug that yielded less than 25 colonies on subculture (95% lysis of the initial inoculum).
RESULTS
The in vitro activity of cefamandole against gram-positive cocci and gram-negative bacilli is shown in Fig. 1 . All ofthe penicillin G-sensitive isolates and 90% of the penicillin G-resistant isolates of S. aureus were inhibited by 0.39 ,ug Table 1) .
The in vitro activity of cefamandole was compared to that of cefoxitin, cephalothin, and cephalexin ( Fig. 2 through 6 ). Cephalothin was the most active cephalosporin against both penicillin G-sensitive and -resistant S. aureus, but cefamandole was only slightly less active. Ce- foxitin and cephalexin were considerably less active than the other two cephalosporins. Cefamandole was the most active cephalosporin against E. coli. At a concentration of 1.56 ,ug/ ml, it inhibited 76% of the isolates, whereas at the same concentration cefoxitin inhibited 28%, and cephalothin and cephalexin inhibited only 5% ofisolates. All four cephalosporins had similar activity against K. pneumoniae. However, only 4% of these isolates was resistant to 25 ,ug of cephalexin per ml, whereas 14% was resistant to the same concentration of cefamandole. Cefamandole was the only cephalosporin that had substantial activity against isolates ofEnterobacter spp. Cefoxitin was the most active cephalosporin against indole-positive Proteus spp., whereas cefamandole was the most active against P. mirabilis. At a concentration of 12.5 ,ug/ml, cefoxitin inhibited 97% of the former isolates and cefamandole inhibited 34%, but cephalothin and cephalexin inhibited less than 10% of the isolates. Although ceftmandole was active against some isolates of S. marcescens, cefoxitin was more active. At a concentration of 50 ,ug/ml, cefamandole inhibited 20% of the isolates, whereas cefoxitin inhibited 52%. Cephalexin and cephalothin were inactive against S. marcescens.
The susceptibility to cefamandole of cephalothin-resistant isolates ofE. coli and K. pneumoniae is shown in Table 2 . Thirteen of these 22 isolates ofE. coli were susceptible to 12.5 ,ug or less of cefamandole per ml. Only 2 of the 18 isolates of K. pneumoniae were susceptible to cefamandole. All eight isolates that were resistant to 100 ,ug of cephalothin per ml were also resistant to 100 gg of cefamandole per ml.
DISCUSSION
Cefamandole was effective in vitro against gram-positive cocci, including penicillin G-resistant isolates of S. aureus. Our results are similar to those of Neu who found that isolates of S. aureus and S. pyogenes were quite sensitive to cefamandole (2). Eykyn et al. compared cefamandole to cephalothin and cephalexin against isolates of S. aureus and found results similar to the present study (1) .
The activity of cefamandole against gramnegative bacilli was impressive since it included some isolates ofEnterobacter spp. and S. marcescens, which usually are resistant to cephalosporins. It was also active against isolates ofE. coli, which were resistant to cephalothin. Cefamandole was superior to cephalothin and cephalexin against E. coli and P. mirabilis, which is in agreement with the results of Neu et al. (2) and Eykyn et al. (1) . In our study these three cephalosporins were equally active against K. pneumoniae, whereas these other investigators found cefamandole to be more active. Although cefamandole was active against most cephalothin-resistant isolates ofE. coli, it was not active against most cephalothin-resistant isolates of K. pneumoniae. Cefamandole is more resistant to degradation by 13-lactamases produced by some gram-negative bacilli, which may explain its activity against cephalothinresistant E. coli (2) . Other mechanisms of resistance exist since strains of gram-negative bacilli that fail to hydrolyze cefamandole also may be resistant (2) . Although cefamandole was active against a few isolates of S. marcescens, it is unlikely to be of clinical importance for the treatment of Serratia infections. In our study cefamandole was bactericidal against most isolates at the MIC. Eykyn et al. found the MBC of many isolates to be considerably higher than the MIC, which is difficult to reconcile with our results (1).
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